Kids with brain tumors are staying off treatment longer — here's why that's a big deal

A 4-year update from the phase 2 FIREFLY-1 trial brings encouraging news for children with relapsed or refractory BRAF-altered low-grade glioma (a common pediatric brain tumor). Tovorafenib — an oral, once-weekly targeted therapy — not only shrank tumors effectively but also allowed many patients to stay completely off treatment for extended stretches after completing their planned course.

Among the 41 patients who entered the post-treatment observation period, the majority enjoyed prolonged treatment-free intervals. Notably, when tumors showed radiographic progression, it often didn't reflect true treatment failure — 77% of those patients still had smaller tumors at the end of treatment than at baseline. For kids who needed retreatment, the drug worked again, with 91% still on retreatment at the data cutoff.

Key Takeaways:

• 76% of patients remained treatment-free for ≥12 months; 54% for ≥24 months after stopping tovorafenib
• Objective response rate held strong at 53% at 4 years, with a median duration of response of 19.4 months
• Median time to next treatment was 50.9 months — well beyond the radiographic progression-free survival of 16.6 months
• 54% experienced tumor rebound after stopping, but retreatment yielded a median best tumor shrinkage of −41%
• No treatment-related deaths occurred; 88% of patients showed growth recovery after growth suppression during treatment

Why it matters: For children with brain tumors, the goal isn't just shrinking tumors — it's giving kids a chance at a normal life. These data suggest tovorafenib can deliver durable disease control, meaningful time off therapy, and a reliable retreatment option, making it a compelling long-term strategy in pediatric neuro-oncology.